Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.0%

1 terminated/withdrawn out of 25 trials

Success Rate

96.0%

+9.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
14(87.5%)
Phase 1
2(12.5%)
16Total
Phase 2(14)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT02601690Terminated

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

Role: lead

NCT02478060Phase 2Completed

Birch-SPIRE Safety and Efficacy Study

Role: collaborator

NCT02396680Completed

Ragweed-SPIRE Follow-On Study

Role: collaborator

NCT02161107Phase 2Completed

Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma

Role: collaborator

NCT02061709Phase 2Completed

Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber

Role: collaborator

NCT02061670Phase 2Completed

Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma

Role: collaborator

NCT02292875Completed

ToleroMune Grass Follow on Study

Role: collaborator

NCT01949441Phase 2Completed

ToleroMune House Dust Mite (HDM) Tolerability Study

Role: collaborator

NCT01383603Phase 1Completed

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis

Role: collaborator

NCT01949415Completed

An Optional Investigation of Biomarkers of Efficacy

Role: collaborator

NCT01923792Completed

ToleroMune House Dust Mite Follow on Study

Role: collaborator

NCT01383590Phase 1Completed

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis

Role: collaborator

NCT01923779Completed

ToleroMune Grass Follow on Study

Role: collaborator

NCT01385800Phase 2Completed

ToleroMune Grass Exposure Unit Study

Role: collaborator

NCT01447784Phase 2Completed

ToleroMune House Dust Mites (HDM) Exposure Chamber Study

Role: collaborator

NCT01604018Completed

An Optional Two Year Follow Up Study to Study CP005A

Role: collaborator

NCT01448603Completed

ToleroMune Ragweed Follow up Study

Role: collaborator

NCT01198613Phase 2Completed

ToleroMune Ragweed Exposure Chamber Study

Role: collaborator

NCT01361412Phase 2Completed

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

Role: collaborator

NCT01166061Phase 2Completed

Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis

Role: collaborator